Positive interim study results for Titan's spheramine

8 August 2001

Titan Pharmaceuticals has presented data which it says furtherdemonstrate improvement in motor function and quality of life for patients treated with its potential Parkinson's disease treatment spheramine.

The interim Phase I/II study results, presented at the International Congress on Parkinson's Disease in Finland, indicate that all six patients in the study experienced substantial clinical improvement, and also suggest a sustained effect after a single treatment, with patients on study ranging from seven-15 months post-treatment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight